Androgen receptor expression in low grade serous ovarian cancer; clinical considerations in the diagnosis, treatment and surveillance of disease in a transgender male.

Autor:	Smrz SA; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals/Case Western Reserve University, Cleveland, OH 44106, United States., Chapman G; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals/Case Western Reserve University, Cleveland, OH 44106, United States., Gordon J; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals/Case Western Reserve University, Cleveland, OH 44106, United States., Bagby C; Department of Pathology, University Hospitals/Case Western Reserve University, Cleveland, OH 44106, United States., Nascimento A; Department of Pathology, University Hospitals/Case Western Reserve University, Cleveland, OH 44106, United States., Ferguson L; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals/Case Western Reserve University, Cleveland, OH 44106, United States.
Jazyk:	angličtina
Zdroj:	Gynecologic oncology reports [Gynecol Oncol Rep] 2023 Apr 15; Vol. 47, pp. 101190. Date of Electronic Publication: 2023 Apr 15 (Print Publication: 2023).
DOI:	10.1016/j.gore.2023.101190
Abstrakt:	•Low grade serous (LGS) ovarian cancer is an uncommon cancer.•Androgen receptor expression testing is not routinely performed in patients with LGS ovarian cancer.•Systemic androgen levels may be elevated in patients with PCOS or those taking exogenous testosterone.•Consideration should be made to include androgen receptor testing for these patients. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2023 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu